Active Ingredient History
Clofarabine is a anti-cancer drug which was approved by FDA for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia. After crossing the cell membrane the drug is rapidly metabolized by deoxycytidine kinase to diphosphate and triphosphate metabolites and these metabolites reversibly inhibit hRNR by binding to alpha subunit. Also the triphosphate is incorporated to DNA where it acts as a chain terminator. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Early Phase 1)
Adrenoleukodystrophy (Phase 2)
Anemia, Aplastic (Phase 2)
Anemia, Refractory (Phase 2)
Bone Marrow Cells (Phase 2)
Bone Marrow Diseases (Phase 1)
Bone Marrow Failure Disorders (Phase 2)
Bone Marrow Transplantation (Phase 3)
Burkitt Lymphoma (Phase 2)
Carcinoma (Early Phase 1)
Gangliosidosis, GM1 (Phase 2)
Graft vs Host Disease (Phase 2)
Hematologic Neoplasms (Phase 1)
Hematopoietic Stem Cell Transplantation (Phase 2)
Hemoglobinopathies (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2)
Hodgkin Disease (Phase 2)
Intestinal Neoplasms (Phase 2)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 3)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myelomonocytic, Acute (Phase 3)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Leukemia, Prolymphocytic (Phase 1/Phase 2)
Leukemia, Promyelocytic, Acute (Phase 1)
Leukemia, T-Cell (Phase 2)
Leukodystrophy, Globoid Cell (Phase 2)
Leukodystrophy, Metachromatic (Phase 2)
Lymphohistiocytosis, Hemophagocytic (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)
Lymphoproliferative Disorders (Phase 1)
Metabolic Diseases (Phase 2)
Mucolipidoses (Phase 2)
Mucopolysaccharidosis III (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2/Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasm, Residual (Phase 2)
Neoplasms ()
Neutropenia (Phase 1)
Osteopetrosis (Phase 2)
Preleukemia (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 2)
Sandhoff Disease (Phase 2)
Sarcoma, Myeloid (Phase 2)
Stem Cell Transplantation (Phase 2)
Tay-Sachs Disease (Phase 2)
Testicular Neoplasms (Phase 3)
Transplantation (Phase 3)
Wolman Disease (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
